311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuerstein also dissect Alnylam's forthcoming clinical trial data and take stock of how the biotech markets are succeeding and potentially falling flat midw…
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry. We also bring on our colleague Jason Mast to talk …
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceutica…
354: Uncertainty in CRISPR world and the start of more M&A
We chat about M&A deals picking up, leadership changes at Novo, and recent FDA advisory committee meetings for cancer drugs. We also bring on STAT reporter Jason Mast to talk about the latest research and sentiment at the annual American Society of Cell and Gene Therapy meeting.
DEKALB® Corn: What Does it Mean to be Silage Proven? (Sponsored Podcast)
Join Jason Mast, Casey Mikus, and Josh Tooley as they recap the 2025 growing season, chat all things harvest, and dive into the DEKALB® Silage breeding process. Learn how DEKALB breeds genetics to be Silage Proven with high quality and tonnage potential.
DEKALB® Silage Proven products are bred to…
376: BridgeBio’s great week and Moderna’s unraveling
Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween?
We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the…
‘Where’s our CRISPR miracle?’
Celena Lozano's son Benny, who turned 5 in November, loves trains, trucks — anything that goes. He also has a rare disease, PURA syndrome.
Earlier this year, when headlines announced that a child with a different rare disease, known as Baby KJ, had been treated using CRISPR in a major breakthrough…
387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial si…
396: A new trick for old science, and biotech VCs' scrambled playbook
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Adam is out, so Elaine and Allison dive into the latest news, including how China and artificial intelligence are straining biotech VC firms, in addition to more M&A. They also discu…
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’…
PODCAST-ZOEKMACHINE
U kunt onze website gebruiken om3,824,406podcasts en195,749,769afleveringen te zoeken op mensen, plaatsen of onderwerpen.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .
